Ten‐year experience in atenolol use and exercise evaluation in children with genetically proven long QT syndrome
Key result
Atenolol in children with LQT1 and LQT2 is linked to a ~1% ventricular arrhythmia rate.
- n=86
Why the study?
Does atenolol prevent ventricular arrhythmias and cardiac arrest in children and adolescents with genetically proven LQT1 and LQT2?
Population
86 children and adolescents with genetically proven long QT syndrome type 1 and type 2, 86% referred for…
Design
Cohort
Follow-up
median 4.29 years
Authors
Discussion
Loading...
Member takes
Implication
Supports atenolol in pediatric LQT1/2; leaves open need for randomized comparisons to other beta-blockers.
Study Design
Type
Observational (n=86)
Multicenter
No
Structured PICO
Does atenolol prevent ventricular arrhythmias and cardiac arrest in children and adolescents with genetically proven LQT1 and LQT2?
P
Population
86 children and adolescents with genetically proven long QT syndrome type 1 (n=67) and type 2 (n=19), 86% referred for family screening
I
Intervention
Atenolol at a mean dose of 1.58 ± 0.51 mg/kg/day
O
Outcome
Ventricular arrhythmia, cardiac arrest, and aborted cardiac arresthard clinical
Atenolol is an effective and well-tolerated treatment for preventing cardiac events in children and adolescents with genetically proven LQT1 and LQT2.
Cite This Study
Kwok et al. (2017) conducted an observational in genetically proven long QT syndrome type 1 (LQT1) and type 2 (LQT2) (n=86). Atenolol was evaluated on ventricular arrhythmia or cardiac arrest. Atenolol treatment in children with LQT1 and LQT2 was effective, with only 1 of 86 patients (1.2%) developing ventricular arrhythmia and no cardiac arrests over a median 4.29 years of follow-up.